Cytomed Therapeutics Limited Stock Market Outlook
| GDTC Stock | 1.02 0.07 7.37% |
About 62% of all CytoMed Therapeutics' shareholders are looking to take a long position. The analysis of the overall investor sentiment regarding CytoMed Therapeutics Limited suggests that some traders are interested. The current market sentiment, together with CytoMed Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use CytoMed Therapeutics stock news signals to limit their universe of possible portfolio assets.
Comfort Level 62
Interested
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use CytoMed Therapeutics' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward CytoMed Therapeutics Limited.
News SentimentBullish | Hype SentimentBullish | Insider SentimentWaiting |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding CytoMed Therapeutics Limited is 'Strong Sell'. Macroaxis provides CytoMed Therapeutics buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding GDTC positions.
Execute CytoMed Therapeutics Advice
The CytoMed recommendation should be used to complement the investment advice compiled from the current analysts' consensus on CytoMed Therapeutics Limited. Macroaxis does not own or have any residual interests in CytoMed Therapeutics Limited or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute CytoMed Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Weakest | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Barely shadows the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
For the selected time horizon CytoMed Therapeutics Limited has a Mean Deviation of 4.21, Standard Deviation of 6.58 and Variance of 43.3We provide trade advice to complement the prevailing expert consensus on CytoMed Therapeutics. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time. To make sure CytoMed Therapeutics is not overpriced, please confirm all CytoMed Therapeutics fundamentals, including its cash flow from operations, market capitalization, and the relationship between the net income and target price . Given that CytoMed Therapeutics is a hitting penny stock territory we recommend to closely look at its shares owned by institutions.
CytoMed Therapeutics Trading Alerts and Improvement Suggestions
| CytoMed Therapeutics generated a negative expected return over the last 90 days | |
| CytoMed Therapeutics has high historical volatility and very poor performance | |
| CytoMed Therapeutics has some characteristics of a very speculative penny stock | |
| The company reported the previous year's revenue of 52.01 K. Net Loss for the year was (1.84 M) with profit before overhead, payroll, taxes, and interest of 675.25 K. | |
| CytoMed Therapeutics generates negative cash flow from operations | |
| CytoMed Therapeutics has a frail financial position based on the latest SEC disclosures | |
| About 67.0% of the company shares are held by company insiders | |
| Latest headline from simplywall.st: CytoMed Therapeutics And 2 More Penny Stocks With Promising Prospects |
CytoMed Therapeutics current analysts advice
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. CytoMed analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. CytoMed analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.
CytoMed Therapeutics Returns Distribution Density
The distribution of CytoMed Therapeutics' historical returns is an attempt to chart the uncertainty of CytoMed Therapeutics' future price movements. The chart of the probability distribution of CytoMed Therapeutics daily returns describes the distribution of returns around its average expected value. We use CytoMed Therapeutics Limited price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of CytoMed Therapeutics returns is essential to provide solid investment analysis for CytoMed Therapeutics.
| Mean Return | -0.78 | Value At Risk | -10.38 | Potential Upside | 8.33 | Standard Deviation | 6.58 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of CytoMed Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
CytoMed Therapeutics Cash Flow Accounts
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Investments | (823.7K) | (473.3K) | (2.8M) | 1.1M | 1.3M | 1.4M | |
| Change In Cash | 1.2M | (683.7K) | 3.5M | (1.3M) | (1.1M) | (1.1M) | |
| Net Borrowings | 291.1K | (128.8K) | (340.4K) | (44.6K) | (40.1K) | (38.1K) | |
| Free Cash Flow | (1.7M) | (1.4M) | (2.7M) | (3.0M) | (2.7M) | (2.8M) | |
| Depreciation | 244.6K | 293.3K | 288.8K | 245.6K | 282.4K | 261.4K | |
| Other Non Cash Items | 327.7K | 1.0M | 256.4K | (39.5K) | (35.5K) | (33.7K) | |
| Capital Expenditures | 431.8K | 353.7K | 44.2K | 1.0M | 1.2M | 1.2M | |
| Net Income | (1.5M) | (2.3M) | (3.1M) | (1.8M) | (1.7M) | (1.7M) | |
| End Period Cash Flow | 1.9M | 1.2M | 4.7M | 3.4M | 4.0M | 2.2M |
CytoMed Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to CytoMed Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that CytoMed Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a CytoMed stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.79 | |
β | Beta against Dow Jones | 0.11 | |
σ | Overall volatility | 6.83 | |
Ir | Information ratio | -0.13 |
CytoMed Therapeutics Volatility Alert
CytoMed Therapeutics Limited is displaying above-average volatility over the selected time horizon. CytoMed Therapeutics Limited is a potential penny stock. Although CytoMed Therapeutics may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in CytoMed Therapeutics Limited. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on CytoMed instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.CytoMed Therapeutics Fundamentals Vs Peers
Comparing CytoMed Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze CytoMed Therapeutics' direct or indirect competition across all of the common fundamentals between CytoMed Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as CytoMed Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of CytoMed Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing CytoMed Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare CytoMed Therapeutics to competition |
| Fundamentals | CytoMed Therapeutics | Peer Average |
| Return On Equity | -0.42 | -0.31 |
| Return On Asset | -0.23 | -0.14 |
| Operating Margin | (4.52) % | (5.51) % |
| Current Valuation | 10.33 M | 16.62 B |
| Shares Outstanding | 11.73 M | 571.82 M |
| Shares Owned By Insiders | 67.35 % | 10.09 % |
| Shares Owned By Institutions | 0.43 % | 39.21 % |
| Number Of Shares Shorted | 14.27 K | 4.71 M |
| Price To Book | 2.20 X | 9.51 X |
| Price To Sales | 15.22 X | 11.42 X |
| Revenue | 52.01 K | 9.43 B |
| Gross Profit | 675.25 K | 27.38 B |
| EBITDA | (1.79 M) | 3.9 B |
| Net Income | (1.84 M) | 570.98 M |
| Total Debt | 339.2 K | 5.32 B |
| Book Value Per Share | 0.62 X | 1.93 K |
| Cash Flow From Operations | (1.69 M) | 971.22 M |
| Short Ratio | 0.10 X | 4.00 X |
| Earnings Per Share | (0.25) X | 3.12 X |
| Target Price | 5.0 | |
| Number Of Employees | 43 | 18.84 K |
| Beta | -0.35 | -0.15 |
| Market Capitalization | 22.53 M | 19.03 B |
| Total Asset | 7.37 M | 29.47 B |
| Retained Earnings | (10.87 M) | 9.33 B |
| Working Capital | 5.39 M | 1.48 B |
| Net Asset | 7.37 M |
Note: CytoMed Therapeutics exotic insider transaction detected [view details]
CytoMed Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as CytoMed . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 10598.82 | |||
| Daily Balance Of Power | 0.5833 | |||
| Rate Of Daily Change | 1.07 | |||
| Day Median Price | 0.96 | |||
| Day Typical Price | 0.98 | |||
| Price Action Indicator | 0.095 | |||
| Period Momentum Indicator | 0.07 |
About CytoMed Therapeutics Buy or Sell Advice
When is the right time to buy or sell CytoMed Therapeutics Limited? Buying financial instruments such as CytoMed Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having CytoMed Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Top Crypto Assets Thematic Idea Now
Top Crypto Assets
An experimental p2p digital currency that is accepted by many vendors in null. The Top Crypto Assets theme has 0 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Top Crypto Assets Theme or any other thematic opportunities.
| View All Next | Launch |
Check out CytoMed Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Will Biotechnology sector continue expanding? Could CytoMed diversify its offerings? Factors like these will boost the valuation of CytoMed Therapeutics. Market participants price CytoMed higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every CytoMed Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.25) | Revenue Per Share | Quarterly Revenue Growth 1.01 | Return On Assets | Return On Equity |
The market value of CytoMed Therapeutics is measured differently than its book value, which is the value of CytoMed that is recorded on the company's balance sheet. Investors also form their own opinion of CytoMed Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CytoMed Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because CytoMed Therapeutics' market value can be influenced by many factors that don't directly affect CytoMed Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CytoMed Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if CytoMed Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, CytoMed Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.